Intarcia Therapeutics Company
Intarcia Therapeutics is a biopharmaceutical company that develops therapies for diseases that require long-term chronic treatment. It offers DUROS, a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides. Intarcia Therapeutics' products include OMEGA DUROS, an interferon delivery device for treating Hepatitis C and ITCA 650, a delivery device that provides type 2 diabetes patients with long-term steady state dosing of an incretin mimetic therapy. Additionally, it develops programs for treating obesity. David Franklin, James M. Ahlers, and Thomas Alessi founded BioMedicines in 1997 that became Intarcia Therapeutics in September 2004. Its headquarters is in Hayward in California with an additional office in Mountain View in California.
Investors
Technology:
Immunotherapy
Industry:
PharmTech
Headquarters:
Hayward, California, United States
Zip:
251-500
Founded Date:
1997-01-01
Employees Number:
251-500
Acquisitions Number:
27
Investors Number:
1683530937
Total Funding:
$50M to $100M
Estimated Revenue:
$50M to $100M
Last Funding Date:
Venture - Series Unknown
Last Funding Type:
busdev@intarcia.com
Register and Claim Ownership